BIOL insider filings

BIOLASE, INC — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-06-12. Screen BIOL transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for BIOL between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — BIOLASE, INC

FiledFormInsiderReported transactionsSource
2023-06-124Yale Kenneth P. — DirectorGrant/award (A): 502,404 (derivative) @ $0EDGAR
2023-06-124OLoughlin Kathleen T — DirectorGrant/award (A): 502,404 (derivative) @ $0EDGAR
2023-06-124Somerman Martha J. DDS, PhD — DirectorGrant/award (A): 518,429 (derivative) @ $0EDGAR
2023-06-124Summerhays Carol Gomez DDS — DirectorGrant/award (A): 491,987 (derivative) @ $0EDGAR
2023-06-124ROPER JESS — DirectorGrant/award (A): 512,821 (derivative) @ $0EDGAR
2023-06-124LORD JONATHAN T MD — DirectorGrant/award (A): 721,154 (derivative) @ $0EDGAR
2023-06-064Bright Jennifer — Chief Financial OfficerGrant/award (A): 58,000 (derivative) @ $0EDGAR
2023-06-064/ABright Jennifer — Chief Financial OfficerGrant/award (A): 58,000 (derivative) @ $0EDGAR
2023-06-064Sandor Steven — Chief Operating OfficerGrant/award (A): 58,000 (derivative) @ $0EDGAR
2023-06-064BEAVER JOHN R — President & CEO, DirectorGrant/award (A): 486,255 (derivative) @ $0EDGAR
2023-05-264Schuler Education Foundation — 10% ownerPurchase (P): 1,307,931 @ $0.61 · Sale (S): 1,847,649 @ $0.55 · Sale (S): 2,137,559 @ $0.54 · Sale (S): 1,733,836 @ $0.55 · Conversion (C): 3,745,000 @ $0.40 · Sale (S): 71,100 @ $0.30 · +9 moreEDGAR
2022-12-084LORD JONATHAN T MD — DirectorSale (S): 3,537 @ $0.75EDGAR
2022-08-124Bright Jennifer — Chief Financial OfficerGrant/award (A): 10,000 (derivative) @ $0 · Grant/award (A): 6,663 (derivative) @ $0EDGAR
2022-08-124Sandor Steven — Chief Operating OfficerGrant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 4,621 (derivative) @ $0EDGAR
2022-08-124BEAVER JOHN R — President & CEO, DirectorGrant/award (A): 31,743 (derivative) @ $0EDGAR
2022-05-134Yale Kenneth P. — DirectorGrant/award (A): 40,927 (derivative) @ $0 · Grant/award (A): 3,200 (derivative) @ $0EDGAR
2022-05-134OLoughlin Kathleen T — DirectorGrant/award (A): 40,927 (derivative) @ $0EDGAR
2022-05-134Somerman Martha J. DDS, PhD — DirectorGrant/award (A): 42,232 (derivative) @ $0EDGAR
2022-05-134Summerhays Carol Gomez DDS — DirectorGrant/award (A): 40,078 (derivative) @ $0EDGAR
2022-05-134ROPER JESS — DirectorGrant/award (A): 41,775 (derivative) @ $0EDGAR
2022-05-124LORD JONATHAN T MD — DirectorGrant/award (A): 58,747 (derivative) @ $0EDGAR
2022-05-024ROPER JESS — DirectorDisposition to issuer (D): 345.86EDGAR
2022-05-024BEAVER JOHN R — President & CEO, DirectorDisposition to issuer (D): 554.79EDGAR
2022-05-024LORD JONATHAN T MD — DirectorDisposition to issuer (D): 1,395.41EDGAR
2022-02-104OLoughlin Kathleen T — DirectorGrant/award (A): 90,000 (derivative) @ $0EDGAR
2022-02-104Somerman Martha J. DDS, PhD — DirectorGrant/award (A): 90,000 (derivative) @ $0EDGAR
2022-02-104Summerhays Carol Gomez DDS — DirectorGrant/award (A): 90,000 (derivative) @ $0EDGAR
2021-12-164LORD JONATHAN T MD — DirectorSale (S): 11,038 @ $0.38EDGAR
2021-12-024BEAVER JOHN R — President & CEO, DirectorPurchase (P): 70,000 @ $0.45EDGAR
2021-08-264OLoughlin Kathleen T — DirectorGrant/award (A): 98,955 (derivative) @ $0EDGAR
2021-08-234Somerman Martha J. DDS, PhD — DirectorGrant/award (A): 98,955 (derivative) @ $0EDGAR
2021-08-234Summerhays Carol Gomez DDS — DirectorGrant/award (A): 98,955 (derivative) @ $0EDGAR
2021-08-234BEAVER JOHN R — President & CEO, DirectorPurchase (P): 35,000 @ $0.61EDGAR
2021-08-134BEAVER JOHN R — President & CEO, DirectorGrant/award (A): 220,000 (derivative) @ $0EDGAR
2021-06-144DiTolla Michael — DirectorGrant/award (A): 104,603 (derivative) @ $0 · Grant/award (A): 110,400 (derivative) @ $0EDGAR
2021-06-144Wagner Elaine C — DirectorGrant/award (A): 104,603 (derivative) @ $0 · Grant/award (A): 138,000 (derivative) @ $0EDGAR
2021-06-144Sato Garrett — DirectorGrant/award (A): 110,888 (derivative) @ $0 · Grant/award (A): 138,000 (derivative) @ $0EDGAR
2021-06-144Lanman Richard B. — DirectorGrant/award (A): 104,603 (derivative) @ $0 · Grant/award (A): 138,000 (derivative) @ $0EDGAR
2021-06-144ROPER JESS — DirectorGrant/award (A): 111,337 (derivative) @ $0 · Grant/award (A): 138,000 (derivative) @ $0EDGAR
2021-06-144BEAVER JOHN R — President & CEO, DirectorGrant/award (A): 4,144,139 (derivative) @ $0EDGAR
2021-06-144LORD JONATHAN T MD — DirectorGrant/award (A): 189,902 (derivative) @ $0 · Grant/award (A): 330,000 (derivative) @ $0EDGAR
2021-05-194BEAVER JOHN R — President & CEO, DirectorPurchase (P): 40,000 @ $0.75EDGAR
2021-03-264BEAVER JOHN R — President & CEO, DirectorGrant/award (A): 100,000 (derivative) @ $0EDGAR
2020-08-104Wagner Elaine C — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2020-08-104Norbe Todd — President and CEO, DirectorGrant/award (A): 200,000 (derivative) @ $0EDGAR
2020-08-104Sato Garrett — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2020-08-104Lanman Richard B. — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2020-08-104ROPER JESS — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2020-08-104BEAVER JOHN R — EVP & Chief Financial OfficerGrant/award (A): 200,000 (derivative) @ $0EDGAR
2020-08-104LORD JONATHAN T MD — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR

Recent 8-K events — BIOLASE, INC

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2024-10-088-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2024-10-018-K1.01 — Entry into a Material Definitive Agreement
1.03 — Bankruptcy or Receivership
2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2024-09-068-K1.01 — Entry into a Material Definitive Agreement
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
9.01 — Financial Statements and Exhibits
EDGAR
2024-08-288-K2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementEDGAR
2024-08-088-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2024-07-228-K3.02 — Unregistered Sales of Equity Securities
9.01 — Financial Statements and Exhibits
EDGAR
2024-06-188-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
9.01 — Financial Statements and Exhibits
EDGAR
2024-05-178-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2024-05-138-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2024-05-068-K5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=BIOL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs